ARTL - Artelo jumps 21% as publication highlights pre-clinical data on drug platform
- Nano-cap stock Artelo Biosciences ( NASDAQ: ARTL ) added ~21% in the morning hours Tuesday after the clinical-stage pharma announced the recent publication of pre-clinical data supporting the potential of its FABP inhibitor therapeutic platform in anxiety-related disorders.
- The research led by academics Taygun C. Uzuneser, Ph.D., and Steven R. Laviolette, Ph.D., at the University of Western Ontario, London, Ontario is based on one of Artelo’s ( ARTL ) FABP inhibitors.
- The preclinical results published in the journal Cerebral Cortex indicate that a fatty acid binding protein 5 (FABP5) inhibitor from ARTL’s FABP inhibitor platform lessens anxiety behaviors in a part of the brain found to be important for anxiety.
- In addition, the research highlights the prospects of modulation of the FABP5 system as a target in the development of novel anxiolytics, the company said.
- “This new data further supports the development of our FABP inhibitor platform in anxiety-related disorders such as post-traumatic stress disorder,” Chief Executive of Artelo ( ARTL ) Gregory D. Gorgas noted.
For further details see:
Artelo jumps 21% as publication highlights pre-clinical data on drug platform